Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 4/20 | 0.39 |
| ▸ | DPP4 | P27487 | 2/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | REN | P00797 | 4/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29396694 | 0.91 | CAPN1 (0.41) | CAPN1OPRM1OPRD1RENCTSB | |
| SCHEMBL31115696 | 0.91 | CAPN1 (0.41) | CAPN1OPRM1OPRD1RENCTSB | |
| SCHEMBL31259075 | 0.90 | CAPN1 (0.44) | CAPN1OPRM1OPRD1CTSBBDKRB2 | |
| SCHEMBL30211634 | 0.89 | CAPN1 (0.43) | CAPN1OPRM1OPRD1RENCTSB | |
| SCHEMBL29376028 | 0.89 | OPRM1 (0.43) | CAPN1OPRM1OPRD1RENCTSB | |
| SCHEMBL29375930 | 0.89 | OPRM1 (0.43) | CAPN1OPRM1OPRD1RENCTSB | |
| SCHEMBL29757422 | 0.88 | CAPN1 (0.51) | CAPN1OPRM1OPRD1CTSB | |
| SCHEMBL30139043 | 0.87 | REN (0.39) | OPRM1OPRD1REN | |
| SCHEMBL31140016 | 0.86 | CAPN1 (0.41) | CAPN1OPRM1OPRD1RENBDKRB2 | |
| SCHEMBL30013216 | 0.86 | CAPN1 (0.41) | CAPN1OPRM1OPRD1RENBDKRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541456-B2 | Roflumilast for the treatment of diabetes mellitus type 2 | TAKEDA GMBH (DE) | 2013-09-24 | — | — | US | disclosed |
| US-20110269750-A1 | ROFLUMILAST FOR THE TREATMENT OF DIABETES MELLITUS | NYCOMED GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269750-A1 | ROFLUMILAST FOR THE TREATMENT OF DIABETES MELLITUS | PPARD, PPARA, PPARG | CAPN1 2238/4885DPP4 64/4885OPRM1 1150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.